Cargando…
2484. Patient Reported Outcomes After Switching to a 2-Drug Regimen of Dolutegravir + Rilpivirine: Week 148 Results from the Sword-1 and Sword-2 Studies
BACKGROUND: The SWORD-1 and SWORD-2 studies previously demonstrated that high rates of virologic suppression were maintained for 148 weeks after switching virologically suppressed HIV-1 infected adults from their current 3- or 4-drug antiretroviral regimen (CAR) to the 2-drug regimen (2DR) of dolute...
Autores principales: | Oglesby, Alan, Angelis, Kostas, Punekar, Yogesh, Chounta, Vasiliki, Antela, Antonio, Matthews, Jessica, Kahl, Lesley, Gartland, Martin, Wynne, Brian, Murray, Miranda, Andre Van Wyk, Jean |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809953/ http://dx.doi.org/10.1093/ofid/ofz360.2162 |
Ejemplares similares
-
Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2
por: Llibre, Josep M., et al.
Publicado: (2022) -
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials
por: van Wyk, Jean, et al.
Publicado: (2020) -
319. SWORD 1 and 2: Switch from TDF Containing Regimen to DTG+RPV Maintains Bone Mineral Density and Decreases Bone Turnover Markers Over 148 Weeks
por: Kahl, Lesley, et al.
Publicado: (2019) -
Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health
por: McComsey, Grace A., et al.
Publicado: (2018) -
Sword 1 and 2: Subgroup Analysis of 48 Week Results by Age, Race and Gender
por: Walmsley, Sharon, et al.
Publicado: (2017)